More Stories

Informist, Saturday, Jan. 31, 2026

 

Please click here to read all liners published on this story

--Sun Pharma: Innovative medicines growth offset fall in generics ops in US
--Sun Pharmaceutical Oct-Dec consolidated earnings detailed table
--Sun Pharma Oct-Dec consol R&D spend INR 8.93 bln, 5.8% of sales
--Sun Pharma Oct-Dec API external sales INR 5.41 bln, down 4.7% on year
--Sun Pharma Q3 Rest of World formulation sales $296 mln, up 14.5% on yr
--Sun Pharma Q3 emerging mkt formulation sales $337 mln, up 21.6% on yr
--Sun Pharma Oct-Dec US formulation sales $477 mln, up 0.6% on year
--Sun Pharma Q3 India formulation sales INR 49.99 bln vs 43.00 bln year ago
--Sun Pharma Oct-Dec consol EBITDA margin 31.9%
--Sun Pharma Oct-Dec consol EBITDA INR 49.49 bln, up 23.4% on year
--Sun Pharma Apr-Dec consol revenue INR 438.50 bln vs INR 396.20 bln yr ago
--Sun Pharma Apr-Dec consol net profit INR 87.65 bln vs INR 87.79 bln yr ago
--Sun Pharma Oct-Dec profit excluding one-time cost, tax credit INR 35.37 bln
--Sun Pharma Q3 net profit includes one-time tax write back of INR 3.22 bln
--Sun Pharma Oct-Dec net profit includes one-time cost INR 4.89 bln
--Sun Pharma interim dividend record date is Feb 5
--Sun Pharma to pay INR 11 per share interim dividend
--Sun Pharma Oct-Dec consol revenue INR 155.21 bln vs INR 136.75 bln yr ago
--Sun Pharma Oct-Dec consol net profit INR 33.69 bln vs INR 29.03 bln yr ago
--Analysts saw Sun Pharma Oct-Dec consol revenue at INR 147.66 bln
--Sun Pharma Oct-Dec consol revenue INR 155.21 bln
--Analysts saw Sun Pharma Oct-Dec consol net profit at INR 29.81 bln
--Sun Pharma Oct-Dec consol net profit INR 33.69 bln
 

 

By Narayana Krishna

 

MUMBAI – Sun Pharmaceutical Industries Ltd. on Saturday reported a consolidated net profit of INR 33.69 billion for the December quarter, up 16% on year and 8% on quarter. The company's net profit was above the analysts' estimates of INR 29.81 billion.

 

The company reported a one-time cost of INR 4.89 billion and a tax write-back of INR 3.22 billion. Excluding these two, the net profit for the company would be INR 35.37 billion.

 

The exceptional costs were related to implementation of the new labour codes and settlement of litigations, while the tax credit was related to acquisitions and intangible assets-related write-backs.

 

Sun Pharma's December quarter consolidated revenue was up 13.5% on year and 7.2% on quarter at INR 155.21 billion against the consensus estimate of INR 147.66 billion.

 

"Our results this quarter demonstrate well-rounded growth across all businesses, prominently led by our branded businesses in India, emerging markets and global innovative medicines. Our innovative product offering has expanded further with the launch of Unloxcyt in the US and the introduction of Ilumya in India," Sun Pharma said, quoting Managing Director Kirti Ganorkar, as saying.

 

Sun Pharma's India formulations revenue for the December quarter was INR 49.9 billion, up 16.2% on year. This segment accounts for 32.3% of the company's total consolidated sales. The country's largest pharmaceutical company by sales said it also holds the biggest market share in the domestic pharma industry at 8.4%. Sun Pharma launched 12 new products during the December quarter, taking its total product launches in India over the nine months till December to 26.

In the US, which accounts for nearly 28% of the company's total sales, the company reported a marginal 0.6% on-year growth at $477 million in Oct-Dec. Sun Pharma said weakness in its US generics business was partly offset by strong sales in its specialty products division during the quarter

The specialty products segment, now renamed as the innovative medicines segment, reported total sales of $423 million. This includes a milestone income of $55 million. Excluding the milestone income, the revenue from the segment was up 13.2%. This segment accounted for 15.7% of the total sales.

In the emerging markets, the company's sales were up 21.6% on year at $337 million. The segment accounted for 19.4% of the total sales. Rest of the world segment sales were up 14.5% on year at $296 million. This segment accounted for 17.1% of the total sales. Sun Pharma reported a 4.7% on-year decline in its active pharmaceutical ingredients business to INR 5.4 billion in the December quarter. 

Sun Pharma's earnings before interest, tax, depreciation, and amortisation for the December quarter was up 23.4% on year at INR 49.49 billion, while EBITDA margin was at INR 31.9%. The company's spending on research and development for the quarter was at INR 8.93 billion, accounting for 5.8% of the sales.

The company's total expenditure for the December quarter was up nearly 10% on year at INR 113.8 billion. Other expenses rose 16.7% on year to INR 48.9 billion, while employee benefit expenses rose 13.3% on year to INR 28.9 billion. Sun Pharma's raw material costs for the quarter increased nearly 29% on year to INR 18.1 billion.

Sun Pharma's research and development pipeline spans across both innovative and generic businesses, while the innovative pipeline includes five novel entities in the clinical stage, Sun Pharma said. 

 

Sun Pharma's board on Saturday approved an interim dividend of INR 11 per share, fixing the record date on Feb. 5. The company's consolidated net profit for Apr-Dec was INR 87.65 billion on a revenue of INR 438.50 billion.

On Friday, Sun Pharma's shares ended 0.4% higher at INR 1,595.30 on the National Stock Exchange.  End

 

US$1 = INR 91.98

 

Edited by Tanima Banerjee

 

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

 

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

 

Informist Media Tel +91 (22) 6985-4000

Send comments to feedback@informistmedia.com

 

© Informist Media Pvt. Ltd. 2026. All rights reserved.